Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with r...
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Sclerotic chronic graft vs. host disease (cGVHD) still has a large impact on morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We performed the first prospective study to test whether sequential therapy of the anti-CD20 antibody rituximab followed by 6 months treatment with tyrosine kinase inhibitor nilotinib...
Alternative Titles
Full title
Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2014956455
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2014956455
Other Identifiers
ISSN
0268-3369
E-ISSN
1476-5365
DOI
10.1038/s41409-018-0158-9
